NASDAQ:MDXG MiMedx Group (MDXG) Stock Forecast, Price & News $5.64 -0.14 (-2.42%) (As of 04:33 PM ET) Add Compare Share Share Today's Range$5.47▼$5.7950-Day Range$3.14▼$6.1452-Week Range$2.43▼$6.41Volume1.22 million shsAverage Volume606,455 shsMarket Capitalization$651.98 millionP/E RatioN/ADividend YieldN/APrice Target$8.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MiMedx Group MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.3% Upside$8.25 Price TargetShort InterestBearish4.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 2 Articles This WeekInsider TradingSelling Shares$520,081 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.08) to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector494th out of 981 stocksSurgical & Medical Instruments Industry49th out of 98 stocks 3.5 Analyst's Opinion Consensus RatingMiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.25, MiMedx Group has a forecasted upside of 46.3% from its current price of $5.64.Amount of Analyst CoverageMiMedx Group has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.04% of the float of MiMedx Group has been sold short.Short Interest Ratio / Days to CoverMiMedx Group has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in MiMedx Group has recently increased by 3.56%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMiMedx Group does not currently pay a dividend.Dividend GrowthMiMedx Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDXG. Previous Next 1.9 News and Social Media Coverage News SentimentMiMedx Group has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MiMedx Group this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for MDXG on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MiMedx Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $520,081.00 in company stock.Percentage Held by Insiders19.90% of the stock of MiMedx Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.56% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MiMedx Group are expected to grow in the coming year, from ($0.08) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiMedx Group is -20.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiMedx Group is -20.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About MiMedx Group (NASDAQ:MDXG) StockMiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.Read More Receive MDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter. Email Address MDXG Stock News HeadlinesJune 5, 2023 | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Upgraded by StockNews.com to "Strong-Buy"May 27, 2023 | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Stock Rating Lowered by StockNews.comJune 8, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 25, 2023 | finance.yahoo.comBreakeven On The Horizon For MiMedx Group, Inc. (NASDAQ:MDXG)May 20, 2023 | americanbankingnews.comMiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells $22,183.05 in StockMay 19, 2023 | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Trading Down 4.7%May 18, 2023 | benzinga.comMiMedx Group President Trades Company's StockMay 15, 2023 | americanbankingnews.comInsider Selling: MiMedx Group, Inc. (NASDAQ:MDXG) CAO Sells $34,809.10 in StockJune 8, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 15, 2023 | americanbankingnews.comMiMedx Group, Inc. (NASDAQ:MDXG) CFO Sells $35,437.68 in StockMay 14, 2023 | americanbankingnews.comInsider Selling: MiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells 5,869 Shares of StockMay 13, 2023 | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Lowered to "Buy" at StockNews.comMay 10, 2023 | americanbankingnews.comMiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells $276,377.04 in StockMay 7, 2023 | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Raised to Strong-Buy at StockNews.comMay 6, 2023 | americanbankingnews.comInsider Selling: MiMedx Group, Inc. (NASDAQ:MDXG) CAO Sells 5,200 Shares of StockMay 6, 2023 | seekingalpha.comMiMedx's Post-Q1 2023 Surge Could Result In Profit-TakingMay 6, 2023 | americanbankingnews.comHC Wainwright Boosts MiMedx Group (NASDAQ:MDXG) Price Target to $9.50May 6, 2023 | americanbankingnews.comMiMedx Group, Inc. (NASDAQ:MDXG) Expected to Earn Q4 2023 Earnings of ($0.01) Per ShareMay 5, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on MiMedx Group (MDXG)May 5, 2023 | americanbankingnews.comMiMedx Group, Inc. Forecasted to Earn Q2 2023 Earnings of ($0.05) Per Share (NASDAQ:MDXG)May 5, 2023 | americanbankingnews.comAnalysts Offer Predictions for MiMedx Group, Inc.'s Q2 2023 Earnings (NASDAQ:MDXG)May 5, 2023 | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Reaches New 12-Month High Following Analyst UpgradeMay 4, 2023 | americanbankingnews.comMiMedx Group, Inc. (NASDAQ:MDXG) Expected to Earn Q2 2023 Earnings of $0.01 Per ShareMay 3, 2023 | finance.yahoo.comMDXG: 1Q:22 Financial ResultsMay 3, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for MiMedx Group (MDXG)May 3, 2023 | msn.comHC Wainwright & Co. Maintains Mimedx Group (MDXG) Buy RecommendationMay 3, 2023 | finance.yahoo.comQ1 2023 MiMedx Group Inc Earnings CallSee More Headlines MDXG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDXG Company Calendar Last Earnings5/02/2023Today6/08/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDXG CUSIPN/A CIK1376339 Webwww.mimedx.com Phone(770) 651-9100Fax678-384-6741Employees811Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.25 High Stock Price Forecast$9.50 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+45.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,200,000.00 Net Margins-11.18% Pretax Margin-8.73% Return on EquityN/A Return on Assets-18.42% Debt Debt-to-Equity RatioN/A Current Ratio3.22 Quick Ratio2.86 Sales & Book Value Annual Sales$267.84 million Price / Sales2.44 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-35.38Miscellaneous Outstanding Shares115,600,000Free Float92,596,000Market Cap$654.30 million OptionableOptionable Beta1.54 Key ExecutivesJoe CapperChief Executive Officer & DirectorRicci S. WhitlowChief Operating Officer & Executive Vice PresidentPeter M. CarlsonChief Financial OfficerDavid H. MasonChief Medical OfficerJohn R. HarperCTO, Senior VP-Research & DevelopmentKey CompetitorsArtivionNYSE:AORTOrthofix MedicalNASDAQ:OFIXIRadimedNASDAQ:IRMDTactile Systems TechnologyNASDAQ:TCMDOrchestra BioMedNASDAQ:OBIOView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 12,411 shares on 6/1/2023Ownership: 0.011%Royce & Associates LPBought 147,000 shares on 5/23/2023Ownership: 0.728%JPMorgan Chase & Co.Bought 21,131 shares on 5/18/2023Ownership: 0.078%New York State Common Retirement FundSold 24,000 shares on 5/18/2023Ownership: 0.041%Castleview Partners LLCSold 2,000 shares on 5/16/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions MDXG Stock - Frequently Asked Questions Should I buy or sell MiMedx Group stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDXG shares. View MDXG analyst ratings or view top-rated stocks. What is MiMedx Group's stock price forecast for 2023? 2 brokers have issued 1-year target prices for MiMedx Group's stock. Their MDXG share price forecasts range from $7.00 to $9.50. On average, they expect the company's stock price to reach $8.25 in the next year. This suggests a possible upside of 45.8% from the stock's current price. View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts. How have MDXG shares performed in 2023? MiMedx Group's stock was trading at $2.78 at the beginning of 2023. Since then, MDXG shares have increased by 103.6% and is now trading at $5.66. View the best growth stocks for 2023 here. When is MiMedx Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our MDXG earnings forecast. How were MiMedx Group's earnings last quarter? MiMedx Group, Inc. (NASDAQ:MDXG) announced its quarterly earnings results on Tuesday, May, 2nd. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03. The business earned $71.68 million during the quarter, compared to the consensus estimate of $63.48 million. What ETFs hold MiMedx Group's stock? ETFs with the largest weight of MiMedx Group (NASDAQ:MDXG) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU) and What is MiMedx Group's stock symbol? MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG." Who are MiMedx Group's major shareholders? MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.88%), State Street Corp (3.24%), Paradigm Capital Management Inc. NY (2.98%), Geode Capital Management LLC (1.90%), Richmond Brothers Inc. (1.52%) and Federated Hermes Inc. (0.82%). Insiders that own company stock include Mark Graves, Peter M Carlson, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan. View institutional ownership trends. How do I buy shares of MiMedx Group? Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MiMedx Group's stock price today? One share of MDXG stock can currently be purchased for approximately $5.66. How much money does MiMedx Group make? MiMedx Group (NASDAQ:MDXG) has a market capitalization of $654.30 million and generates $267.84 million in revenue each year. The company earns $-30,200,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. How many employees does MiMedx Group have? The company employs 811 workers across the globe. How can I contact MiMedx Group? MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The official website for the company is www.mimedx.com. The company can be reached via phone at (770) 651-9100, via email at investorrelations@mimedx.com, or via fax at 678-384-6741. This page (NASDAQ:MDXG) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.